J Derm TreatComment
Commentary on benefit-risk profile comparison between dupilumab and upadacitinib
a structured benefit-risk assessment of the heads up trial.
Yılmaz E, Koker Özer N, Topal E
Journal of Dermatological Treatment28 September 2026
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
More on Biologics and JAK inhibitors & other targeted pills
PubMed 42803499(opens in a new tab)Issue 2026 Dec · DOI 10.1080/09546634.2026.2735534